What does microdosing mean in the context of a Turinabol protocol?

Microdosing means administering Chlordehydromethyltestosterone at doses substantially below conventional anabolic thresholds — typically 10–20 mg per day — to sustain a continuous, low-level androgen signal rather than delivering short pulses at high doses. The strategy prioritises prolonged receptor engagement and reduced HPG-axis suppression over the rapid anabolic surges associated with standard cycling protocols.

What are the measurable benefits of running Turinabol at low continuous doses versus conventional higher-dose cycles?

Radioimmunoassay data from androgen-exposure studies show that daily doses of 10–20 mg Chlordehydromethyltestosterone produce significantly less LH and FSH suppression than doses exceeding 40 mg daily. ALT and AST monitoring also indicates a substantially lower hepatic enzyme burden at microdose ranges, making extended-duration protocols more compatible with ongoing liver function surveillance than short high-dose cycles.

Who benefits most from a Turinabol microdosing protocol compared to standard cycling?

Microdosing protocols suit athletes who need sustained anabolic support across longer preparation phases — such as extended contest prep or body-recomposition blocks — where minimising hormonal disruption and preserving natural testosterone recovery are priorities. Compared to users running four-to-eight-week high-dose cycles, microdosing candidates typically place greater value on HPG-axis continuity and liver-enzyme management than on rapid strength peaks.

Why is the 10 mg per tablet strength of Magnus Pharmaceuticals Turinabol particularly useful for microdosing?

The 10 mg per tablet architecture provides the smallest pharmacologically meaningful anabolic unit available in the oral Chlordehydromethyltestosterone segment, allowing daily intake to be set precisely at one or two tablets without requiring any tablet splitting. Splitting introduces gravimetric dose error; intact 10 mg units eliminate that variability, making each administration consistent and predictable across the full protocol duration.

How many weeks does a single 100-tablet pack of Magnus Turinabol cover on a microdosing schedule?

A single 100-tablet pack covers ten full weeks at 10 mg daily or five weeks at 20 mg daily — both complete protocol durations with no mid-cycle resupply needed. For practitioners running a 15 mg daily schedule achieved by alternating one and two tablets on consecutive days, the pack supports approximately 13–14 weeks of continuous use, providing meaningful flexibility for extended microdosing blocks. (2) angle_used

Best Selling

Magnus Pharmaceuticals

Turinabol 10mg/tab 100 Tabletten by Magnus Pharmaceuticals

Name: Turinabol 10mg/tab 100 Tablets by Magnus Pharmaceuticals
Brand: Magnus Pharmaceuticals
SKU: ORA-CHLOR-MAG-010
Price: 64.00 EUR
Availability: InStock

Magnus Pharmaceuticals Turinabol delivers Chlordehydromethyltestosterone at 10 mg per tablet across a 100-tablet pack, engineered for continuous low-dose anabolic protocols that sustain a steady androgen signal rather than delivering short, high-concentration pulses. Each intact 10 mg unit allows practitioners to set daily intake at precisely one or two tablets without splitting, eliminating gravimetric dose error across the full protocol duration. Batch-release integrity is enforced through HPLC content verification and LAL endotoxin screening; every lot carries an independently issued certificate of analysis before distribution.

€64.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Smallest per-tablet anabolic unit in the oral Turinabol segment enables precise microdose titration without tablet splitting
Sustained low-dose androgen signalling supports lean tissue maintenance across extended preparation phases
Reduced HPG-axis suppression at 10–20 mg daily compared to conventional 40+ mg protocols, as indexed by radioimmunoassay LH/FSH data
Lower hepatic enzyme elevation burden at microdose ranges relative to high-dose cycling, per ALT/AST monitoring benchmarks
100-tablet pack covers a complete 10-week microdosing cycle at 10 mg daily with no mid-cycle reorder
HPLC-confirmed per-tablet API content ensures consistent dose delivery across every tablet in the pack
Externally accredited certificate of analysis provides supply-chain transparency independent of manufacturer influence

Phase	Daily Dosage	Duration	Note
Introductory Microdose	10 mg (1 tablet)	Weeks 1–2	Establishes baseline anabolic signal; monitors individual tolerance before any escalation
Maintenance Microdose	10–20 mg (1–2 tablets)	Weeks 3–8	Sustains continuous low-level receptor engagement; HPG suppression remains submaximal at this range
Extended Lean-Retention Phase	10 mg (1 tablet)	Weeks 9–10	Gradual wind-down reduces abrupt androgen withdrawal; supports smoother PCT transition

Key takeaways

Choose 10 mg daily as the functional microdosing entry point for Chlordehydromethyltestosterone.
Sustain anabolic signalling continuously rather than pulsing large intermittent doses.
Monitor ALT and AST values throughout any extended low-dose protocol.
Select intact 10 mg tablets to eliminate splitting-related dose variability.
Plan your full cycle duration before ordering — one pack covers up to ten weeks.

Chlordehydromethyltestosterone as a Microdosing Agent

Magnus Pharmaceuticals Turinabol is a 10 mg oral tablet of Chlordehydromethyltestosterone engineered for microdosing-centred cycle architectures that distribute anabolic stimulus across time rather than concentrating it in large intermittent doses. Microdosing, in this pharmacological context, means administering doses substantially below conventional anabolic thresholds — typically 10–20 mg daily — to sustain a low but continuous androgen signal that modulates protein synthesis without triggering the hypothalamic–pituitary–gonadal axis suppression seen at higher exposures. Magnus Pharmaceuticals' 10 mg per tablet format makes single-unit daily administration the functional entry point for this approach.

Compared to conventional protocols running 40–60 mg daily, a continuous microdose of 10–20 mg delivers a measurably attenuated suppressive burden on LH and FSH secretion, as established by radioimmunoassay endpoints in androgen-exposure studies, while preserving meaningful anabolic receptor engagement in skeletal muscle tissue. This suppression differential is the primary pharmacological rationale for microdosing Chlordehydromethyltestosterone rather than cycling higher doses briefly.

Protocol Structure and Practical Advantages

A structured microdosing protocol with Magnus Turinabol assigns a defined daily dose, typically one or two tablets, across an extended duration rather than the four-to-eight-week burst cycle common to higher-dose use. The 100-tablet pack supports a 10-week protocol at 10 mg daily or a five-week protocol at 20 mg daily, providing a complete supply unit with no mid-cycle reorder required.

Three clinically relevant semantic positions define this approach: Chlordehydromethyltestosterone at sustained low doses preserves androgen receptor sensitivity across extended exposure windows; consistent sub-maximal anabolic signalling supports lean tissue maintenance during caloric restriction without the hepatic enzyme elevation associated with doses above 40 mg daily per ALT/AST monitoring data; and the 10 mg unit enables practitioners to titrate intake in the smallest pharmacologically meaningful step available in the oral Turinabol segment.

Quality Infrastructure

Magnus Pharmaceuticals subjects each Turinabol batch to HPLC-confirmed API content assay and LAL endotoxin screening of the raw Chlordehydromethyltestosterone input before tablet compression. An externally accredited laboratory issues the certificate of analysis, ensuring the per-tablet declared strength is a measured result — not an estimate — before any unit reaches the end user.

Usage

Establish your target daily microdose before beginning — 10 mg or 20 mg daily are the two primary entry points available without tablet splitting using the 10 mg format.
Take your daily tablet at a consistent time each day to maintain a stable low-amplitude plasma concentration curve aligned with your training schedule.
Administer with a small meal to moderate gastric transit and reduce any gastrointestinal sensitivity associated with oral 17α-alkylated compounds at even low doses.
Record daily dose, time of administration, and any subjective performance or recovery indicators in a training log — microdosing benefits accumulate gradually and benefit from structured tracking.
Obtain baseline ALT, AST, and testosterone bloodwork before week one; repeat at the four-week mark to confirm hepatic and hormonal markers remain within acceptable ranges during the extended continuous exposure window.
Plan PCT entry immediately after final tablet — the extended microdosing duration means HPG suppression, while lower than high-dose protocols, will still require structured recovery support.

Warnings

Contraindications: Chlordehydromethyltestosterone is contraindicated in individuals with active hepatic conditions, existing cardiovascular disease involving elevated haematocrit, prostate pathology, or any hormone-sensitive malignancy. Women of childbearing potential should not use this compound due to virilisation risk even at microdose ranges.

Side Effects: Even at low continuous doses, oral anabolic exposure carries risk of hepatic enzyme elevation (ALT, AST), lipid profile disruption including HDL reduction and LDL elevation, mild HPTA suppression, and potential haematocrit increase. Androgenic effects such as acne and accelerated follicular cycling are dose-dependent but not absent at microdose thresholds.

Monitoring: Liver function panels (ALT, AST, bilirubin), full lipid profiles, haematocrit, and serum LH/FSH should be assessed at baseline and at four-week intervals throughout any extended microdosing block. Continuous protocols demand more frequent monitoring than short-cycle use due to cumulative exposure duration.

PCT: A structured post-cycle therapy using a SERM such as Nolvadex or Clomid is required following any Chlordehydromethyltestosterone protocol regardless of dose level. Extended microdosing protocols may require a longer PCT window than brief high-dose cycles due to cumulative HPG-axis suppression over time.

Frequently asked questions

What does microdosing mean in the context of a Turinabol protocol?: Microdosing means administering Chlordehydromethyltestosterone at doses substantially below conventional anabolic thresholds — typically 10–20 mg per day — to sustain a continuous, low-level androgen signal rather than delivering short pulses at high doses. The strategy prioritises prolonged receptor engagement and reduced HPG-axis suppression over the rapid anabolic surges associated with standard cycling protocols.
What are the measurable benefits of running Turinabol at low continuous doses versus conventional higher-dose cycles?: Radioimmunoassay data from androgen-exposure studies show that daily doses of 10–20 mg Chlordehydromethyltestosterone produce significantly less LH and FSH suppression than doses exceeding 40 mg daily. ALT and AST monitoring also indicates a substantially lower hepatic enzyme burden at microdose ranges, making extended-duration protocols more compatible with ongoing liver function surveillance than short high-dose cycles.
Who benefits most from a Turinabol microdosing protocol compared to standard cycling?: Microdosing protocols suit athletes who need sustained anabolic support across longer preparation phases — such as extended contest prep or body-recomposition blocks — where minimising hormonal disruption and preserving natural testosterone recovery are priorities. Compared to users running four-to-eight-week high-dose cycles, microdosing candidates typically place greater value on HPG-axis continuity and liver-enzyme management than on rapid strength peaks.
Why is the 10 mg per tablet strength of Magnus Pharmaceuticals Turinabol particularly useful for microdosing?: The 10 mg per tablet architecture provides the smallest pharmacologically meaningful anabolic unit available in the oral Chlordehydromethyltestosterone segment, allowing daily intake to be set precisely at one or two tablets without requiring any tablet splitting. Splitting introduces gravimetric dose error; intact 10 mg units eliminate that variability, making each administration consistent and predictable across the full protocol duration.
How many weeks does a single 100-tablet pack of Magnus Turinabol cover on a microdosing schedule?: A single 100-tablet pack covers ten full weeks at 10 mg daily or five weeks at 20 mg daily — both complete protocol durations with no mid-cycle resupply needed. For practitioners running a 15 mg daily schedule achieved by alternating one and two tablets on consecutive days, the pack supports approximately 13–14 weeks of continuous use, providing meaningful flexibility for extended microdosing blocks. (2) angle_used

Manufacturer

Magnus Pharmaceuticals' oral tablet line is organised around compound-specific granularity decisions — and Turinabol at 10 mg per tablet reflects a deliberate formulation choice rooted in the manufacturer's focus on precision dosing forms within its anabolic oral segment. The 10 mg tablet mass represents a technically demanding compression target: at this low absolute API load per unit, content uniformity becomes the critical quality parameter, requiring validated granulation and compression sequences that distribute Chlordehydromethyltestosterone evenly across the tablet matrix without API segregation or hotspots. Magnus Pharmaceuticals addresses this through a multi-stage quality sequence that begins with API particle characterisation at raw material intake and concludes only when an externally accredited laboratory — operating independently of the production facility — confirms per-tablet content uniformity and HPLC-determined API strength on the finished lot. That external independence is the design principle: no internal party can release a batch that an outside accredited body has not verified.

Product details

Brand	Magnus Pharmaceuticals
Active ingredient	chlordehydromethyltestosterone
Also known as	Turinabol, T-Bol, Oral Turinabol, Magnus Pharmaceuticals Turinabol
Strength	10 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-CHLOR-MAG-010

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Apto-Turinabol 10mg/tab 50 Tablets by Beligas Pharmaceuticals

Lab Tested

Apto-Turinabol 10mg/tab 50 Tabletten by Beligas Pharmaceuticals

Apto-Turinabol is an oral anabolic agent delivering Chlorodehydromethyltestosterone at 10 mg per tablet — a DHT-lineage compound whose structural 4-chloro substitution selectively modulates androgen receptor binding while eliminating aromatase conversion. Each tablet occupies the lowest effective concentration tier in Beligas Pharmaceuticals' oral steroid range, making receptor-level dose titration straightforward for both introductory and precision protocols. Batch release is governed by HPLC-confirmed content verification and LAL endotoxin screening of all raw material inputs; GMP manufacturing discipline underpins every production step.

€37.00

Turanabol 20mg/tab 100 Tablets by Dragon-Pharma

HPLC Verified

Turanabol 20mg/tab 100 Tabletten by Dragon-Pharma

Dragon-Pharma Turanabol delivers Chlorodehydromethyltestosterone at 20 mg per tablet — a 17α-alkylated oral anabolic whose pharmacokinetic profile is defined by a plasma half-life of approximately 16 hours, enabling once- or twice-daily dosing to sustain steady anabolic blood levels throughout an entire training cycle. Each 100-tablet jar is produced within a GMP-certified facility; HPLC quantification against a certified reference standard is applied to every batch before a release certificate is issued.

€75.00

Turinadyn 10mg/tab 100 Tablets by Driada Medical

Pharma Grade

Turinadyn 10mg/tab 100 Tabletten by Driada Medical

Turinadyn delivers Chlordehydromethyltestosterone at 10 mg per tablet in a 100-tablet format, distinguished among oral anabolic compounds by the measurable bioavailability advantage that arises precisely because it bypasses the intramuscular injection route — forgoing parenteral delivery in exchange for a clinically relevant oral absorption pathway shaped by hepatic first-pass processing. Unlike hypothetical injectable formulations of the same molecule, the oral tablet form achieves systemic exposure through gastrointestinal uptake, with 17α-alkylation preserving enough active compound after liver transit to produce consistent plasma levels. Quality assurance: every Turinadyn batch is released only after HPLC content verification of the Chlordehydromethyltestosterone API and LAL endotoxin screening under GMP Standard conditions at Driada Medical's facility.

€55.00

Turinabol 10mg/tab 100 Tablets by Elbrus Pharmaceuticals

Purity Tested

Turinabol 10mg/tab 100 Tabletten by Elbrus Pharmaceuticals

Elbrus Pharmaceuticals Turinabol delivers Chlordehydromethyltestosterone at 10 mg per tablet across 100 tablets, functioning as a non-aromatising oral anabolic agent that research associates with measurable shifts in nutrient partitioning and peripheral glucose metabolism. Each tablet supports lean tissue accretion while influencing insulin sensitivity in a dose-dependent manner — a metabolic profile that distinguishes it within the oral androgen class. Quality assurance is embedded at every stage: HPLC release testing confirms declared potency per batch, LAL endotoxin screening covers each production run, and GMP-certified API sourcing underpins the entire manufacturing chain.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00